目的：探讨磁共振弥散加权成像（DWI）、表观扩散系数（ADC）对乳腺癌化疗疗效的评价。方法：选取我院2014年3月—2016年3月的45例化疗的乳腺癌进行MRI的疗效的诊断分析，化疗前进行MRI检查，化疗2~3月后再进行MRI检查，比较肿瘤大小，ADC值变化，增强扫描的横轴位及曲线的变化等。结果：化疗前的肿瘤大小（29.9±10.3） mm及体积大小（22 689.2±1 090.5） mm3与化疗后的肿瘤大小（12.6±5.3） mm和体积大小（15 042.9±211.2） mm3存在明显差异（P＜0.05）；化疗后患者的ADCmean值（1 102.6±102.3）×10-6 mm2/s和ADCmin值（1 042.9±211.2）×10-6 mm2/s明显高于化疗前（849.9±120.3） mm2和（715.2±100.5） mm2/s，具有统计学意义（P＜0.05）；化疗前后时间-信号强度曲线（TIC）类型由Ⅲ型向Ⅰ型变化的趋势，且差异有统计学意义（P＜0.05）。结论：乳腺癌化疗后进行MRI评价可以明显观察患者的病灶变化及ADC的变化，进行化疗后患者的曲线由Ⅲ型向Ⅰ型变化的趋势。
Abstract
Objective: To study the efficacy of DWI and ADC in the treatment of breast cancer. Methods: From March 2014 to March 2016, we selected 45 cases of chemotherapy of breast cancer to analyze efficacy of MRI diagnosis. All of the patients underwent MRI examination before chemotherapy and after chemotherapy for three months, compared before and after chemotherapy on tumor size, ADC value, enhanced scanning of the sagittal and time-intensity curve(TIC) changes. Results: The size of tumor was (29.9±10.3) mm and the volume of (22 689.2±1 090.5) mm3 before chemotherapy and tumor size was (12.6±5.3) mm and volume of (15 042.9±211.2) mm3 after chemotherapy which had obvious difference(P<0.05). After chemotherapy in patients with ADCmean (1 102.6±102.3)×10-6 mm2/s and ADCmin (1 042.9±211.2)×10-6 mm2/s was significantly higher than that before chemotherapy (849.9±120.3) mm2 and (715.2±100.5) mm2/s, with statistical significance(P<0.05); before and after chemotherapy, the TIC type changed by the type Ⅲ to Ⅰ, and the difference was statistically significant(P<0.05). Conclusion: MRI evaluation after chemotherapy for breast cancer can reflect observe the changes of the lesions including ADC, and the trend of the change of TIC type Ⅲ to Ⅰ in patients after chemotherapy.
关键词
乳腺肿瘤 /
抗肿瘤联合化疗方案 /
磁共振成像
Key words
Breast neoplasms /
Antineoplastic combined chemotherapy protocols /
Magnetic resonance imaging
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1]夏碗君，王祥超，李功杰，等. 磁共振成像在乳腺癌新辅助化疗疗效评估中的应用[J]. 军事医学，2012，36（1）：56-59.
[2]杨露，毛伟明. MRI增强扫描与ADC序列观察肿瘤退缩率对乳腺癌化疗疗效的评估价值[J]. 中国CT和MRI杂志，2016，14（5）：62-65.
[3]Wu LM, Xu JR, Gu HY, et al. Preoperative mediastinal and hilar nodal staging with diffusion-weighted magnetic resonance imaging and fluorodeoxyglucose positron emission tomography/computed tomography in patients with non-small-cell lung cancer: which is better?[J]. J Surg Res, 2012, 178(1): 304-314.
[4]周礼金，李晓杰，纪婷，等. 磁共振动态增强VIEWS及弥散加权成像DWI在乳腺癌保乳术前评估的价值[J]. 中国CT和MRI杂志，2015，13（5）：74-76.
[5]Tsuchida T, Morikawa M, Demura Y, et al. Imaging the early response to chemotherapy in advanced lung cancer with diffusion-weighted magnetic resonance imaging compared to fluorine-18 fluorodeoxy glucose positron emission tomography and computed tomography[J]. J Magn Reson Imaging, 2013, 38(1): 80-88.
[6]姜蕾. 乳腺MRI评价乳腺癌新辅助化疗疗效中的应用[J]. 肿瘤影像学，2013，22（2）：151-154.
[7]王长河. 局部进展期乳腺癌新辅助化疗应用磁共振灌注成像的临床疗效研究[J]. 中国CT和MRI杂志，2015，13（2）：34-37.
[8]朱艳，陆洋，王娅婷，等. 表观扩散系数在乳腺癌肝转移早期疗效评价中的应用[J]. 临床放射学杂志，2015，34（7）：1097-1101.
[9]Weber MA, Bender K, von Gall CC, et al. Assessment of diffusion weighted MRI and 18F-fluoro-deoxyglucose PET/CT in monitoring early response to neoadjuvant chemotherapy in adenocarcinoma of the esophagogastric junction[J]. J Gastr Liver Dis, 2013, 22(1): 45-52.
[10]王艳，权毅. MRI在乳腺癌新辅助化疗中的应用[J]. 现代临床医学，2016，42（1）：28-30.
[11]李富，曾健，李春燕，等. 磁共振成像表观扩散系数对乳腺癌新辅助化疗的疗效评估[J]. 中国现代医学杂志，2015，25（17）：66-69.
[12]胡丽霞，马捷，贾桂静，等. 磁共振在评价乳腺癌新辅助化疗疗效中的应用[J]. 黑龙江医学，2016，40（6）：523-525.
[13]Heijmen L, Verstappen MC, Ter Voert EE, et al. Tumor response prediction by diffusion-weighted MR imaging: ready for clinical use?[J]. Crit Rev Oncol Hematol, 2012, 83(2): 194-207.
[14]王卫理，丁勇俊，范晓芳. 磁共振弥散加权成像在乳腺癌新辅助化疗疗效监测中的应用价值[J]. 江苏医药，2013，39（11）：1314-1316.
[15]舒虹，段文峰，廖茜，等. MRI动态增强联合弥散加权诊断三阴性乳腺癌的临床研究[J]. 江西医药，2014，49（11）：1144-1146.
